Medicure Stock Price, News & Analysis

Medicure Inc. (OTC PINK: MCUJF) reported its financial results for the year and quarter ending December 31, 2022. The company achieved a total net revenue of $23.1 million, up from $21.7 million in 2021. For Q4 2022, revenue was $6.3 million, slightly down from $6.8 million in Q4 2021. Key revenue drivers included AGGRASTAT^® sales of $11.7 million and ZYPITAMAG^® sales of $3.6 million. Adjusted EBITDA increased to $3.3 million from $2.1 million in the prior year. Net income was reported at $1.4 million or $0.13 per share, compared to a loss of $727,000 in 2021. Despite the positive overall financial performance, Medicure made a marketing hold on sodium nitroprusside due to poor commercial viability.

Medicure Inc. (OTC PINK: MCUJF) will announce its 2022 Year End Financial Results via a conference call on April 10, 2023, at 8:30 AM ET. These results will be filed after market close on April 6, 2023. The call will include a Q&A session for stakeholders to address financial performance and operational questions. Medicure specializes in pharmaceutical development for the U.S. cardiovascular market, marketing drugs like AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a pharmacy enhancing healthcare access nationwide.

Medicure announced the resignation of Board member Gerald McDole, effective January 31, 2023. McDole, who served since 2004, was recognized for his valuable contributions. Additionally, the company granted stock options totaling 1,205,000 shares at $1.25 each to directors, officers, and employees, pending approval from the TSX Venture Exchange. Medicure remains focused on its cardiovascular products in the U.S., including AGGRASTAT^® and ZYPITAMAG^®. The company aims to improve healthcare access through its pharmacy, Marley Drug, which serves various U.S. locations.

Medicure Inc. reported Q3 2022 results with total net revenue of $5.3 million, up from $4.9 million in Q3 2021. Key contributors included AGGRASTAT® ($3.1 million), ZYPITAMAG® ($434,000), and Marley Drug® ($1.8 million). Adjusted EBITDA reached $1.4 million, compared to $282,000 last year. Net income improved to $1.1 million or $0.11 per share, compared to a net loss of $946,000 or $0.09 per share in Q3 2021. The company had unrestricted cash of $4.5 million as of September 30, 2022.

Medicure will present its Q3 2022 financial results via a conference call on November 25, 2022, at 8:30 AM Eastern Time. The financial results will be filed after the market closes on November 24, 2022. Medicure focuses on pharmaceuticals for the U.S. cardiovascular market, marketing AGGRASTAT^® and ZYPITAMAG^® through its subsidiary, Medicure Pharma Inc. The call will include a Q&A session, and a recording will be available afterward on the company's investor relations page.

The press release details the filing of an Early Warning Report by Dr. Albert D. Friesen regarding his increased ownership of Medicure Inc. shares. As of September 22, 2022, Dr. Friesen acquired an additional 14,100 Common Shares at $1.00 each, raising his total to 2,554,027 shares, or 24.91% of the company. This acquisition surpasses the 2% ownership threshold that triggers reporting obligations. Dr. Friesen also holds options for an additional 146,500 shares, increasing his total to 25.97% on a partially diluted basis. The report will be filed according to applicable securities laws.

Medicure reported Q2 2022 results with total net revenue of $5.7 million, up from $5.1 million year-over-year. Revenue from AGGRASTAT® rose to $2.9 million, while ZYPITAMAG® increased to $1.1 million. Marley Drug's revenue decreased slightly to $1.8 million. Adjusted EBITDA was negative $210,000 compared to positive $158,000 in Q2 2021. The net loss widened to $683,000 due to increased R&D costs. Unrestricted cash improved to $4.8 million from $2.5 million. The full results are available on Medicure's website.